Join this workshop to navigate the engineering trade-offs required to unlock the potential of costimulatory engagers in solid tumors.

• Discussing criteria for the selection of high value targets that require conditional activation to protect healthy tissue
• Analyzing the pros and cons of masking the TAA binder versus the CD3 binder
• Identifying the most robust protease-cleavable linkers and stable building blocks
• Discussing models to stimulate the human TME protease levels
• Strategies for evaluating the PK of post-cleaved active product vs pro-drug masked state
• Defining minimum preclinical data set required to justify the complexity of a conditional molecule over a regular one